Ceapro Dividend

Dividend criteria checks 0/6

Ceapro does not have a record of paying a dividend.

Key information

n/a

Dividend yield

n/a

Payout ratio

Industry average yield	3.9%
Next dividend pay date	n/a
Ex dividend date	n/a
Dividend per share	n/a
Earnings per share	-CA$0.036
Dividend yield forecast in 3Y	n/a

Recent dividend updates

No updates

Recent updates

Ceapro Inc. (CVE:CZO) Stock's Been Sliding But Fundamentals Look Decent: Will The Market Correct The Share Price In The Future?

Nov 28

Stability and Growth of Payments

Fetching dividends data

Stable Dividend: Insufficient data to determine if CZO's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if CZO's dividend payments have been increasing.

Dividend Yield vs Market

Ceapro Dividend Yield vs Market

How does CZO dividend yield compare to the market?
Segment	Dividend Yield
Company (CZO)	n/a
Market Bottom 25% (CA)	1.9%
Market Top 25% (CA)	6.5%
Industry Average (Chemicals)	3.9%
Analyst forecast in 3 Years (CZO)	n/a

Notable Dividend: Unable to evaluate CZO's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate CZO's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.

Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate CZO's payout ratio to determine if its dividend payments are covered by earnings.

Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as CZO has not reported any payouts.

Discover strong dividend paying companies

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Ceapro Dividend

Dividend criteria checks 0/6

Key information

Recent dividend updates

Recent updates

Aeterna Zentaris Inc. (TSX:AEZS) entered into a definitive agreement to acquire Ceapro Inc. (TSXV:CZO) for CAD 21.4 million in a merger of equals.

Third quarter 2023 earnings released: CA$0.013 loss per share (vs CA$0.011 profit in 3Q 2022)

Ceapro Inc. Initiates Phase 1-2A Study Assessing Its Product Avenanthramides for Potential Applications in Inflammation Based Diseases

Ceapro Inc. Initiates Phase 1-2A Study Assessing Its Product Avenanthramides for Potential Applications in Inflammation Based Diseases

Second quarter 2023 earnings released: CA$0.015 loss per share (vs CA$0.021 profit in 2Q 2022)

The Returns At Ceapro (CVE:CZO) Aren't Growing

Ceapro Inc. Announces Resignation of Glenn Rourke as A Director

First quarter 2023 earnings released: CA$0.005 loss per share (vs CA$0.026 profit in 1Q 2022)

Ceapro Inc. Presents Encouraging Results from Research Collaboration Study with McMaster University Evaluating PGX-Processed Yeast Beta Glucan for Interstitial Lung Diseases

Full year 2022 earnings released: EPS: CA$0.056 (vs CA$0.037 in FY 2021)

Ceapro Inc. Receives Approval from Health Canada to Commence Phase 1/2A Human Clinical Trial Assessing Avenanthramide Tablets

Third quarter 2022 earnings released: EPS: CA$0.011 (vs CA$0.011 in 3Q 2021)

Ceapro Inc. Launches Next Phase of Scale Up for Disruptive PGX Technology to Pursue Product Development for Nutraceutical and Pharmaceutical Markets

Returns At Ceapro (CVE:CZO) Are On The Way Up

Ceapro Inc. Announces Positive Data from Bioavailability Studies Evaluating CoQ10 Formulations Impregnated with PGX-Processed Carriers

Second quarter 2022 earnings released: EPS: CA$0.021 (vs CA$0.009 in 2Q 2021)

Ceapro Inc. Appoints Sigrun Watson as Chief Revenue Officer

Ceapro's (CVE:CZO) Returns Have Hit A Wall

Ceapro Inc. Appoints Ronnie Miller as Chairman of the Board and Genevieve Foster Will Chair the Audit Committee

High number of new directors

First quarter 2022 earnings released: EPS: CA$0.026 (vs CA$0.007 in 1Q 2021)

Insufficient new directors

Ceapro Inc. Announces Appointment of Geneviève Foster to Board of Directors

Full year 2021 earnings released: EPS: CA$0.037 (vs CA$0.024 in FY 2020)

Ceapro Inc., Annual General Meeting, Jun 01, 2022

Ceapro Appoints Ronnie Miller to its Board of Directors

Ceapro Appoints Ronnie Miller to its Board of Directors

Ceapro (CVE:CZO) Will Want To Turn Around Its Return Trends

Third quarter 2021 earnings released: EPS CA$0.011 (vs CA$0.002 in 3Q 2020)

Second quarter 2021 earnings released

Be Wary Of Ceapro (CVE:CZO) And Its Returns On Capital

Ceapro Inc. Announces Completion of Patient Enrollment in Clinical Study Evaluating Beta Glucan as A Cholesterol-Lowering Agent

Ceapro's (CVE:CZO) Robust Earnings Are Supported By Other Strong Factors

First quarter 2021 earnings released

Estimating The Fair Value Of Ceapro Inc. (CVE:CZO)

Full year 2020 earnings released

New 90-day low: CA$0.63

Will Ceapro (CVE:CZO) Multiply In Value Going Forward?

Is It Too Late To Consider Buying Ceapro Inc. (CVE:CZO)?

New 90-day high: CA$0.79

Estimating The Fair Value Of Ceapro Inc. (CVE:CZO)

Ceapro Inc. (CVE:CZO) Stock's Been Sliding But Fundamentals Look Decent: Will The Market Correct The Share Price In The Future?

New 90-day high - CA$0.84

Stability and Growth of Payments

Dividend Yield vs Market

Earnings Payout to Shareholders

Cash Payout to Shareholders

Discover strong dividend paying companies